AMAG's Makena Fails Confirmatory Pre-Term Birth Study, But May Not Be Pulled From Market
Executive SummaryThe company will conduct subgroup analyses to support ongoing use, but analysts believe Makena is unlikely to be pulled from the market when compounded progesterone is the only alternative therapy. Nevertheless, sales already are declining, since generics launched last year.
You may also be interested in...
Taking on critics who say it is too quick to award accelerated approval based on surrogate endpoints and limited safety data, agency's 25-year review shows cancer drugs receiving accelerated approval generally have twice the amount of safety data as efficacy, and more than half have confirmed clinical benefit after approval.
AMAG Pharmaceuticals has been on the lookout for assets to add to its bag of marketed products for the past few years and now the company will pay up to $1bn to buy Lumara Health, formerly KV Pharmaceutical, which emerged from bankruptcy a year ago.
Blaming the US FDA for some its woes, KV Pharmaceuticals over the weekend revealed it had filed for Chapter 11 bankruptcy protection, hoping to get out from under its debt.